false 2024 Q3 --01-31 0001512886 Unlimited Unlimited P3Y 0001512886 2023-02-01 2023-10-31 0001512886 2023-12-15 0001512886 2023-10-31 0001512886 2023-01-31 0001512886 us-gaap:SeriesAPreferredStockMember 2023-10-31 0001512886 us-gaap:SeriesAPreferredStockMember 2023-01-31 0001512886 us-gaap:SeriesBPreferredStockMember 2023-10-31 0001512886 us-gaap:SeriesBPreferredStockMember 2023-01-31 0001512886 us-gaap:SeriesCPreferredStockMember 2023-10-31 0001512886 us-gaap:SeriesCPreferredStockMember 2023-01-31 0001512886 us-gaap:SeriesEPreferredStockMember 2023-10-31 0001512886 us-gaap:SeriesEPreferredStockMember 2023-01-31 0001512886 us-gaap:SeriesFPreferredStockMember 2023-10-31 0001512886 us-gaap:SeriesFPreferredStockMember 2023-01-31 0001512886 us-gaap:SeriesGPreferredStockMember 2023-10-31 0001512886 us-gaap:SeriesGPreferredStockMember 2023-01-31 0001512886 2022-02-01 2023-01-31 0001512886 2023-08-01 2023-10-31 0001512886 2022-08-01 2022-10-31 0001512886 2022-02-01 2022-10-31 0001512886 us-gaap:CommonStockMember 2022-01-31 0001512886 us-gaap:SeriesAPreferredStockMember 2022-01-31 0001512886 us-gaap:SeriesBPreferredStockMember 2022-01-31 0001512886 us-gaap:SeriesCPreferredStockMember 2022-01-31 0001512886 us-gaap:SeriesEPreferredStockMember 2022-01-31 0001512886 us-gaap:SeriesFPreferredStockMember 2022-01-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001512886 us-gaap:RetainedEarningsMember 2022-01-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-01-31 0001512886 2022-01-31 0001512886 us-gaap:CommonStockMember 2022-04-30 0001512886 us-gaap:SeriesAPreferredStockMember 2022-04-30 0001512886 us-gaap:SeriesBPreferredStockMember 2022-04-30 0001512886 us-gaap:SeriesCPreferredStockMember 2022-04-30 0001512886 us-gaap:SeriesEPreferredStockMember 2022-04-30 0001512886 us-gaap:SeriesFPreferredStockMember 2022-04-30 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001512886 us-gaap:RetainedEarningsMember 2022-04-30 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-04-30 0001512886 2022-04-30 0001512886 us-gaap:CommonStockMember 2022-07-31 0001512886 us-gaap:SeriesAPreferredStockMember 2022-07-31 0001512886 us-gaap:SeriesBPreferredStockMember 2022-07-31 0001512886 us-gaap:SeriesCPreferredStockMember 2022-07-31 0001512886 us-gaap:SeriesEPreferredStockMember 2022-07-31 0001512886 us-gaap:SeriesFPreferredStockMember 2022-07-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001512886 us-gaap:RetainedEarningsMember 2022-07-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-07-31 0001512886 2022-07-31 0001512886 us-gaap:CommonStockMember 2023-01-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001512886 us-gaap:RetainedEarningsMember 2023-01-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-01-31 0001512886 us-gaap:CommonStockMember 2023-04-30 0001512886 us-gaap:SeriesAPreferredStockMember 2023-04-30 0001512886 us-gaap:SeriesBPreferredStockMember 2023-04-30 0001512886 us-gaap:SeriesCPreferredStockMember 2023-04-30 0001512886 us-gaap:SeriesEPreferredStockMember 2023-04-30 0001512886 us-gaap:SeriesFPreferredStockMember 2023-04-30 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001512886 us-gaap:RetainedEarningsMember 2023-04-30 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-04-30 0001512886 2023-04-30 0001512886 us-gaap:CommonStockMember 2023-07-31 0001512886 us-gaap:SeriesAPreferredStockMember 2023-07-31 0001512886 us-gaap:SeriesBPreferredStockMember 2023-07-31 0001512886 us-gaap:SeriesCPreferredStockMember 2023-07-31 0001512886 us-gaap:SeriesEPreferredStockMember 2023-07-31 0001512886 us-gaap:SeriesFPreferredStockMember 2023-07-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-07-31 0001512886 us-gaap:RetainedEarningsMember 2023-07-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-07-31 0001512886 2023-07-31 0001512886 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0001512886 us-gaap:SeriesAPreferredStockMember 2022-02-01 2022-04-30 0001512886 us-gaap:SeriesBPreferredStockMember 2022-02-01 2022-04-30 0001512886 us-gaap:SeriesCPreferredStockMember 2022-02-01 2022-04-30 0001512886 us-gaap:SeriesEPreferredStockMember 2022-02-01 2022-04-30 0001512886 us-gaap:SeriesFPreferredStockMember 2022-02-01 2022-04-30 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0001512886 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-02-01 2022-04-30 0001512886 2022-02-01 2022-04-30 0001512886 us-gaap:CommonStockMember 2022-05-01 2022-07-31 0001512886 us-gaap:SeriesAPreferredStockMember 2022-05-01 2022-07-31 0001512886 us-gaap:SeriesBPreferredStockMember 2022-05-01 2022-07-31 0001512886 us-gaap:SeriesCPreferredStockMember 2022-05-01 2022-07-31 0001512886 us-gaap:SeriesEPreferredStockMember 2022-05-01 2022-07-31 0001512886 us-gaap:SeriesFPreferredStockMember 2022-05-01 2022-07-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-07-31 0001512886 us-gaap:RetainedEarningsMember 2022-05-01 2022-07-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-05-01 2022-07-31 0001512886 2022-05-01 2022-07-31 0001512886 us-gaap:CommonStockMember 2022-08-01 2022-10-31 0001512886 us-gaap:SeriesAPreferredStockMember 2022-08-01 2022-10-31 0001512886 us-gaap:SeriesBPreferredStockMember 2022-08-01 2022-10-31 0001512886 us-gaap:SeriesCPreferredStockMember 2022-08-01 2022-10-31 0001512886 us-gaap:SeriesEPreferredStockMember 2022-08-01 2022-10-31 0001512886 us-gaap:SeriesFPreferredStockMember 2022-08-01 2022-10-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-08-01 2022-10-31 0001512886 us-gaap:RetainedEarningsMember 2022-08-01 2022-10-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-08-01 2022-10-31 0001512886 us-gaap:CommonStockMember 2023-02-01 2023-04-30 0001512886 us-gaap:SeriesAPreferredStockMember 2023-02-01 2023-04-30 0001512886 us-gaap:SeriesBPreferredStockMember 2023-02-01 2023-04-30 0001512886 us-gaap:SeriesCPreferredStockMember 2023-02-01 2023-04-30 0001512886 us-gaap:SeriesEPreferredStockMember 2023-02-01 2023-04-30 0001512886 us-gaap:SeriesFPreferredStockMember 2023-02-01 2023-04-30 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-30 0001512886 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-30 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-02-01 2023-04-30 0001512886 2023-02-01 2023-04-30 0001512886 us-gaap:CommonStockMember 2023-05-01 2023-07-31 0001512886 us-gaap:SeriesAPreferredStockMember 2023-05-01 2023-07-31 0001512886 us-gaap:SeriesBPreferredStockMember 2023-05-01 2023-07-31 0001512886 us-gaap:SeriesCPreferredStockMember 2023-05-01 2023-07-31 0001512886 us-gaap:SeriesEPreferredStockMember 2023-05-01 2023-07-31 0001512886 us-gaap:SeriesFPreferredStockMember 2023-05-01 2023-07-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-05-01 2023-07-31 0001512886 us-gaap:RetainedEarningsMember 2023-05-01 2023-07-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-05-01 2023-07-31 0001512886 2023-05-01 2023-07-31 0001512886 us-gaap:CommonStockMember 2023-08-01 2023-10-31 0001512886 us-gaap:SeriesAPreferredStockMember 2023-08-01 2023-10-31 0001512886 us-gaap:SeriesBPreferredStockMember 2023-08-01 2023-10-31 0001512886 us-gaap:SeriesCPreferredStockMember 2023-08-01 2023-10-31 0001512886 us-gaap:SeriesEPreferredStockMember 2023-08-01 2023-10-31 0001512886 us-gaap:SeriesFPreferredStockMember 2023-08-01 2023-10-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-08-01 2023-10-31 0001512886 us-gaap:RetainedEarningsMember 2023-08-01 2023-10-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-08-01 2023-10-31 0001512886 us-gaap:CommonStockMember 2022-10-31 0001512886 us-gaap:SeriesAPreferredStockMember 2022-10-31 0001512886 us-gaap:SeriesBPreferredStockMember 2022-10-31 0001512886 us-gaap:SeriesCPreferredStockMember 2022-10-31 0001512886 us-gaap:SeriesEPreferredStockMember 2022-10-31 0001512886 us-gaap:SeriesFPreferredStockMember 2022-10-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2022-10-31 0001512886 us-gaap:RetainedEarningsMember 2022-10-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2022-10-31 0001512886 2022-10-31 0001512886 us-gaap:CommonStockMember 2023-10-31 0001512886 us-gaap:AdditionalPaidInCapitalMember 2023-10-31 0001512886 us-gaap:RetainedEarningsMember 2023-10-31 0001512886 ntrr:StockSubscribedButNotIssuedMember 2023-10-31 0001512886 us-gaap:SeriesGPreferredStockMember 2023-02-01 2023-10-31 0001512886 us-gaap:EquipmentMember 2023-10-31 0001512886 ntrr:MrJimMember srt:ChiefExecutiveOfficerMember 2023-10-31 0001512886 ntrr:DeityCorporationMember 2023-10-31 0001512886 us-gaap:EquipmentMember 2023-01-31 0001512886 srt:ChiefExecutiveOfficerMember 2023-02-01 2023-10-31 0001512886 srt:ChiefExecutiveOfficerMember 2022-02-01 2022-10-31 0001512886 srt:ChiefExecutiveOfficerMember 2022-02-01 2023-01-31 0001512886 ntrr:MrJimMember srt:ChiefExecutiveOfficerMember 2023-02-01 2023-10-31 0001512886 srt:ChiefExecutiveOfficerMember ntrr:AccountsPayableRelatedPartyAndAdvancesPayableToRelatedPartyMember 2023-10-31 0001512886 srt:ChiefExecutiveOfficerMember ntrr:AccountsPayableRelatedPartyAndAdvancesPayableToRelatedPartyMember 2023-01-31 0001512886 2022-03-11 0001512886 srt:ChiefExecutiveOfficerMember ntrr:MrJimMember 2022-01-31 0001512886 us-gaap:SeriesAPreferredStockMember 2020-01-31 0001512886 us-gaap:SeriesAPreferredStockMember ntrr:VIVISCorporationMember 2020-01-01 2020-01-31 0001512886 us-gaap:SeriesBPreferredStockMember 2020-07-31 0001512886 us-gaap:SeriesBPreferredStockMember ntrr:VIVISCorporationMember 2020-07-01 2020-07-31 0001512886 us-gaap:SeriesBPreferredStockMember 2021-01-31 0001512886 us-gaap:SeriesBPreferredStockMember 2020-02-01 2021-01-31 0001512886 us-gaap:SeriesCPreferredStockMember 2020-11-30 0001512886 us-gaap:SeriesCPreferredStockMember ntrr:VIVISCorporationMember 2020-11-01 2020-11-30 0001512886 us-gaap:ConvertiblePreferredStockMember 2020-11-30 0001512886 us-gaap:SeriesCPreferredStockMember 2020-11-01 2020-11-30 0001512886 us-gaap:SeriesCPreferredStockMember 2021-01-31 0001512886 us-gaap:SeriesCPreferredStockMember 2020-02-01 2021-01-31 0001512886 us-gaap:SeriesEPreferredStockMember 2015-11-13 0001512886 us-gaap:SeriesEPreferredStockMember 2015-11-12 2015-11-13 0001512886 us-gaap:SeriesFPreferredStockMember 2023-02-01 2023-10-31 0001512886 us-gaap:SeriesFPreferredStockMember srt:ChiefExecutiveOfficerMember 2021-01-31 0001512886 us-gaap:SeriesFPreferredStockMember 2021-01-31 0001512886 us-gaap:SeriesGPreferredStockMember 2022-10-31 0001512886 2022-02-23 0001512886 2022-02-21 2022-02-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~October~~April 3130, ~~2023~~2024

[_]	TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number: 0-55077

NEUTRA CORP.

(Exact name of registrant as specified in its charter)

Wyoming		27-4505461
(State or other jurisdiction of Incorporation or organization)		(I.R.S. Employer Identification Number)
54 Sugar Creek Center Blvd., Suite 200 Sugar Land, Texas		77478
2500 CityWest Blvd., Ste 150-161 Houston, Texas		77042
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: ~~702~~(307) 228-~~793-4121~~1488

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

[X] Yes [_] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

[X_] Yes [_X] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[_]	Accelerated filer	[_]
Non-accelerated filer	[X]	Smaller reporting company	[X]
		Emerging growth company	[_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[_] Yes [X] No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of ~~December~~August 156, ~~2023~~2024, 2,917,899,124 shares of common stock are issued and outstanding.

Explanatory Note

The Company is filing this Form 10-Q including its interim consolidated financial statements on an unaudited and unreviewed basis. No Registered Independent Public Accounting Firm has completed a review under applicable guidelines for the three-month period ended April 30, 2024.

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION
Item 1. Financial Statements	4
Consolidated Balance Sheets (unaudited)	4
Consolidated Statements of Operations (unaudited)	5
Consolidated Statements of Stockholders’ Deficit (unaudited)	6
Consolidated Statement of Changes in Mezzanine Equity(unaudited)	7
Consolidated Statements of Cash Flows (unaudited)	8
Notes to the Unaudited Consolidated Financial Statements	9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3. Quantitative and Qualitative Disclosures about Market Risk	16
Item 4. Controls and Procedures	16
PART II — OTHER INFORMATION
Item 1. Legal Proceedings	17
Item 1A. Risk Factors	17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3. Defaults upon Senior Securities	17
Item 4. Mine Safety Disclosures	17
Item 5. Other Information	17
Item 6. Exhibits	17
Signatures	18

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements	4

Consolidated Balance Sheets (unaudited)	4

Consolidated Statements of Operations (unaudited)	5

Consolidated Statements of Stockholders’ Deficit (unaudited)	6

Consolidated Statements of Cash Flows (unaudited)	8

Notes to the Unaudited Consolidated Financial Statements	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3. Quantitative and Qualitative Disclosures about Market Risk	15

Item 4. Controls and Procedures	15

PART II — OTHER INFORMATION

Item 1. Legal Proceedings	16

Item 1A. Risk Factors	16

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	16

Item 3. Defaults upon Senior Securities	16

Item 4. Mine Safety Disclosures	16

Item 5. Other Information	16

Item 6. Exhibits	16

Signatures	17

- 2 -

Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this report contain or may contain forward-looking statements. These statements, identified by words such as “plan”, “anticipate”, “believe”, “estimate”, “should”, “expect” and similar expressions include our expectations and objectives regarding our future financial position, operating results and business strategy. These statements are subject to known and unknown risks, uncertainties and other factors, which may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward - looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, our ability to secure suitable financing to continue with our existing business or change our business and conclude a merger, acquisition or combination with a business prospect, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this report in its entirety, including but not limited to our financial statements and the notes thereto and the risks described in our Annual Report on Form 10-K for the fiscal year ended January 31, ~~2023~~2024. We advise you to carefully review the reports and documents we file from time to time with the Securities and Exchange Commission (the “SEC”), particularly our quarterly reports on Form 10-Q and our current reports on Form 8-K. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

OTHER PERTINENT INFORMATION

When used in this report, the terms, “we,” the “Company,” “our,” and “us” refers to Neutra Corp., a Wyoming corporation.

- 3 -

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

NEUTRA CORP.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	October 31,			January 31,
	April 30,			January 31,
	2023			2023
	2024			2024
	(UNAUDITED)			(AUDITED)
CURRENT ASSETS
Cash and cash equivalents	$	~~692~~333		$	1,~~969~~632
Accounts Receivable		98			—
Accounts receivable		98			98
Inventory		18,610			23,846
Total current assets		431			1,730
Total current assets		19,400			25,815
Property and equipment, net		—			1,121
Property and equipment, net		7,544			49,360
TOTAL ASSETS	$	431		$	2,851
TOTAL ASSETS	$	26,944		$	75,175
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	~~480~~483,~~974~~578		$	~~516~~474,~~890~~823
Accounts payable to related party		~~407~~427,~~768~~920			~~233~~423,~~087~~610
Advances payable		3,450			3,450
Advances payable to related party		12,314			212,314
Dividends payable on Series G preferred stock		—			2,062
Notes payable, related party		—			54,156
Accrued interest payable		46,~~322~~043			15,~~836~~176
Total current liabilities		~~908~~987,~~828~~461			~~759~~973,~~639~~529
Notes payable, related party		~~54,156~~—			~~54,156~~—
TOTAL LIABILITIES		~~962~~987,~~984~~461			~~813~~973,~~795~~529
COMMITMENTS AND CONTINGENCIES
MEZZANINE EQUITY
Series G preferred stock; $1.00 stated value, 0 shares and 35,200 shares issued and outstanding at October 31, 2023 and January 31, 2023, respectively		—			35,200
Series G preferred stock; $1.00 stated value, 0 shares issued and outstanding at April 30, 2024 and January 31, 2024, respectively		—			—
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value; unlimited shares authorized; 2,917,899,124 and 2,743,575,314 shares issued and outstanding at October 31, 2023 and January 31, 2023, respectively		2,917,899			2,743,575
Common stock, $0.001 par value; unlimited shares authorized; 2,917,899,124 shares issued and outstanding at April 30, 2024 and January 31, 2024, respectively		2,917,898			2,917,898
Preferred stock, $0.001 par value; 20,000,000 shares authorized:
Series A convertible preferred stock; 50,000 shares issued and outstanding at October 31, 2023 and January 31, 2023		50			50
Series A convertible preferred stock; 50,000 shares issued and outstanding at April 30, 2024 and January 31, 2024		50			50
Series B convertible preferred stock; 10,000 and 0 shares issued and outstanding at October 31, 2023 and January 31, 2023		10			10
Series B convertible preferred stock; 10,000 and 0 shares issued and outstanding at April 30, 2024 and January 31, 2024		10			10
Series C convertible preferred stock; 40,000 shares issued and outstanding at October 31, 2023 and January 31, 2023		40			40
Series C convertible preferred stock; 40,000 shares issued and outstanding at April 30, 2024 and January 31, 2024		40			40
Series E preferred stock, 1,000,000 shares issued and outstanding at October 31, 2023 and January 31, 2023		1,000			1,000
Series E preferred stock, 1,000,000 shares issued and outstanding at April 30, 2024 and January 31, 2024		1,000			1,000
Series F preferred stock, $0.001 par value; 1,000,000 shares issued and outstanding at October 31, 2023 and January 31, 2023		1,000			1,000
Series F preferred stock, $0.001 par value; 1,000,000 shares issued and outstanding at April 30, 2024 and January 31, 2024		1,000			1,000
Additional paid-in capital		7,751,~~840~~839			7,~~889~~751,~~555~~839
Preferred stock subscribed but not issued		50,000			50,000
Accumulated deficit		(11,~~657~~708,~~879~~867	)		(11,~~459~~692,~~050~~515	)
TOTAL STOCKHOLDERS' DEFICIT		(~~936~~987,~~040~~030	)		(~~773~~970,~~820~~678	)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT	$	~~26,944~~431		$	752,~~175~~851

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 4 -

Table of Contents

NEUTRA CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended						~~Nine Months Ended~~
	October 31,						October 31,
	April 30,
	2023			2022			2023			2022
	2024			2023
REVENUE	$	132,~~311~~375		$	235,~~383~~842		$	~~11,478~~		$	~~62,077~~
Cost of goods sold		~~722~~1,420			123,~~708~~038			~~6,403~~			~~29,725~~
Gross margin		~~589~~30,955			102,~~675~~804			~~5,075~~			~~32,352~~
OPERATING EXPENSES
Depreciation		91,~~051~~121			19,726			~~41,816~~			~~59,179~~
Sales commissions		~~779~~1,773			103,~~584~~505			~~6,879~~			~~26,101~~
General and administrative expenses		43,~~487~~546			4650,~~439~~781			~~152,085~~			~~186,958~~
Total operating expenses		5346,~~317~~440			7674,~~749~~012			~~200,780~~			~~272,238~~
LOSS FROM OPERATIONS		(5215,~~728~~485	)		(6671,~~074~~208	)		~~(195,705~~	)		~~(239,886~~	)
OTHER INCOME (EXPENSE)
Interest expense		(~~2,258~~867	)		(~~15,718~~199	)		~~(2,486~~	)		~~(46,528~~	)
Total other income (expense)		(~~2,258~~867	)		(~~15,718~~199	)		~~(2,486~~	)		~~(46,528~~	)
Net loss before income taxes		(5416,~~986~~352	)		(8171,~~792~~407	)		~~(198,191~~	)		~~(286,414~~	)
Provision for income taxes		—			—(589	)		~~(638~~	)		—
Net loss		(54,986	)		(81,792	)		(198,829	)		(286,414	)
NET LOSS	$	(16,352	)	$	(71,996	)
Dividends on Series G convertible preferred stock		—			~~(573~~—	)		—			~~(4,105~~	)
Deemed dividend on Series G convertible preferred stock		—			—			—			(10,200	)
Net loss available to common shareholders	$	(16,352	)	$	(71,996	)
Net loss available to common shareholders	$	(54,986	)	$	(82,365	)	$	(198,829	)	$	(300,719	)
Net loss per common share	$	(0.00	)	$	(0.00	)
Net loss per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted average shares outstanding – basic and diluted		2,917,899,124			2,910,381,521
Weighted average shares outstanding - basic and diluted		2,917,899,124			2,300,718,171			2,914,202,623			2,187,836,449

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 5 -

Table of Contents

NEUTRA CORP.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

				Series A																					Stock
				Convertible			Series B			Series C			Series E			Series F			Additional						subscribed		Total
	Common stock			Preferred Stock			Preferred Stock			Preferred Stock			Preferred Stock			Preferred Stock			paid-in			Accumulated			but not		Equity
	Shares	Par		Shares	Par		Shares	Par		Shares	Par		Shares	Par		Shares	Par		capital			Deficit			issued		(Deficit)
Balance, January 31, 2022	1,782,073,799	$	1,782,074	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,824,982		$	(10,882,188	)	$	—	$	(1,273,032	)
Common stock issued for preferred stock conversions	425,622,150		425,622	—		—	—		—	—		—	—		—	—		—		(199,110	)		—			—		226,512
Preferred stock subscribed but not issued	—		—	—		—	—		—	—		—	—		—	—		—		—			—			50,000		50,000
Dividends on Series G preferred stock	—		—	—		—	—		—	—		—	—		—	—		—		—			(2,429	)		—		(2,429	)
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(107,196	)				(107,196	)
Balance, April 30, 2022	2,207,695,949	$	2,207,696	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,625,872		$	(10,991,813	)	$	50,000	$	(1,106,145	)
Common stock issued for preferred stock conversions	93,022,222		93,022	—		—	—		—	—		—	—		—	—		—		(59,535	)		—			—		33,487
Dividends on Series G preferred stock	—		—	—		—	—		—	—		—	—		—	—		—		—			(1,103	)		—		(1,103	)
Deemed dividend on Series G convertible preferred stock	—		—	—		—	—		—	—		—	—		—	—		—		—			(10,200	)		—		(10,200	)
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(97,426	)				(97,426	)
Balance, July 31, 2022	2,300,718,171	$	2,300,718	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,566,337		$	(11,100,542	)	$	50,000	$	(1,181,387	)
Dividends on Series G convertible preferred stock	—		—	—		—	—		—	—		—	—		—	—		—		—			(573	)		—		(573	)
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(81,792	)				(81,792	)
Balance, October 31, 2022	2,300,718,171	$	2,300,718	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,566,337		$	(11,182,907	)	$	50,000	$	(1,263,752	)
Balance, January 31, 2023	2,743,575,314	$	2,743,575	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,889,555		$	(11,459,050	)	$	50,000	$	(773,820	)
Common stock issued for preferred stock conversions	174,323,810		174,~~324~~323	—		—	—		—	—		—	—		—	—		—		(137,~~715~~716	)		—			—		36,~~609~~607
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(71,996	)		—		(71,996	)
Balance, April 30, 2023	2,917,899,124	$	2,917,~~899~~898	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,751,~~840~~839		$	(11,531,046	)	$	50,000	$	(809,~~207~~209	)
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(71,847	)		—		(71,847	)
Balance, January 31, 2024	2,917,899,124	$	2,917,898	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,751,839		$	(11,692,515	)	$	50,000	$	(970,678	)
Balance, July 31, 2023	2,917,899,124	$	2,917,899	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,751,840		$	(11,602,893	)	$	50,000	$	(881,054	)
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(16,352	)		—		(16,352	)
Net loss	—		—	—		—	—		—	—		—	—		—	—		—		—			(54,986	)		—		(54,986	)
Balance, April 30, 2024	2,917,899,124	$	2,917,898	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,751,839		$	(11,708,867	)	$	50,000	$	(987,030	)
Balance, October 31, 2023	2,917,899,124	$	2,917,899	50,000	$	50	10,000	$	10	40,000	$	40	1,000,000	$	1,000	1,000,000	$	1,000	$	7,751,840		$	(11,657,879	)	$	50,000	$	(936,040	)

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 6 -

Table of Contents

NEUTRA CORP.

CONSOLIDATED ~~STATEMENT~~STATEMENTS OF ~~CHANGES~~CASH ~~IN MEZZANINE EQUITY~~FLOWS

(UNAUDITED)

	Series G Preferred Stock
		Three Months Ended
	Shares			Amount
		April 30,
Balance, January 31, 2023		35,200		$	35,200
		2024			2023
Series G preferred stock converted to common stock		(35,200	)		(35,200	)
CASH FLOW FROM OPERATING ACTIVITIES:
Balance, October 31, 2023		—		$	—
Net loss		$	(16,352	)	$	(71,996	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			1,121			19,726
Changes in operating assets and liabilities
Inventory			—			2,514
Accounts payable and accrued liabilities			10,692			(24,780	)
Accounts payable to related party			2,373			65,506
Accrued interest payable			867			199
NET CASH USED IN OPERATING ACTIVITIES			(1,299	)		(8,831	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advance from related party			—			10,000
NET CASH PROVIDED BY FINANCING ACTIVITIES			—			10,000
NET CHANGE IN CASH AND CASH EQUIVALENTS			(1,299	)		1,169
Cash and cash equivalents at beginning of period			1,632			1,969
Cash and cash equivalents at end of period		$	333		$	3,138
Cash paid during the period for:
Interest		$	—		$	—
Taxes		$	—		$	—
Noncash investing and financing transactions:
Conversion of Series G preferred stock		$	—		$	36,609
Expenses paid on the Company’s behalf		$	1,938		$	—

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 7 -

Table of Contents

NEUTRA CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Nine Months Ended
	October 31,
	2023			2022
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$	(198,829	)	$	(286,414	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		41,816			59,179
Changes in operating assets and liabilities
Accounts Receivable		(98	)		—
Inventory		5,236			(26,810	)
Accounts payable and accrued liabilities		21,637			(23,271	)
Accounts payable to related party		116,475			76,332
Accrued interest payable		2,486			46,228
NET CASH USED IN OPERATING ACTIVITIES		(11,277	)		(154,756	)
CASH FLOWS FROM FINANCING ACTIVITIES
Stock subscriptions received		—			50,000
Proceeds from sale of Series G convertible preferred stock		—			50,000
Proceeds from advance from related party		10,000			—
Proceeds from issuance of note payable		—			60,000
Repayments on notes payable		—			(5,844	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		10,000			154,156
NET CHANGE IN CASH AND CASH EQUIVALENTS		(1,277	)		(600	)
Cash and cash equivalents at beginning of period		1,969			1,056
Cash and cash equivalents at end of period	$	692		$	456
Cash paid during the period for:
Interest	$	—		$	—
Taxes	$	—		$	—
Noncash investing and financing transactions:
Conversion of Series G preferred stock	$	36,609		$	250,000
Dividends on mezzanine equity	$	—		$	4,105
Deemed dividend on mezzanine equity	$	—		$	10,200
Expenses paid on the Company’s behalf	$	58,206		$	—

The accompanying footnotes are an integral part of these unaudited consolidated financial statements.

- 8 -

Table of Contents

NEUTRA CORP.

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

~~October~~April 3130, ~~2023~~2024

Note 1. Background Information

Neutra Corp. was incorporated in Nevada on January 11, 2011, to market and participate in the nutraceutical space by bringing products derived from all natural and organic origins. Along with participating in the actual nutraceutical products, we plan to research and bring new technology to the nutraceutical space. Nutraceutical natural medicine is an alternative system that focuses on natural remedies and the body’s vital ability to heal and maintain itself. One of the nutraceutical sub-markets is the new thriving medical cannabis market, in which we intend to participate. We intend to entrust the manufacturing to a nutraceutical contractor to private label all of our products and to sell them under our unique brand. We have established a fiscal year end of January 31.

As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how it grows, what it grows and how it consumes cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, Neutra Corp. is constantly combing the industry for the latest and greatest to test, prove and bring to market.

Note 2. Going Concern

For the ~~nine~~three months ended ~~October~~April 3130, ~~2023~~2024, the Company had a net loss of $~~198~~16,~~829~~352 and did not have positive cash flow from operations. As of ~~October~~April 3130, ~~2023~~2024, the Company has negative working capital of $~~889~~987,~~428~~030. We have generated limited revenues to date and our activities have been primarily limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business.

Management has plans to address the Company’s financial situation as follows:

In the near term, management plans to continue to focus on raising the funds necessary to implement the Company’s business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company’s financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raises doubts about the Company’s ability to continue as a going concern.

In the long term, management believes that the Company’s projects and initiatives will be successful and will provide cash flow to the Company that will be used to finance the Company’s future growth. However, there can be no assurances that the Company’s planned activities will be successful, or that the Company will ultimately attain profitability. The Company’s long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

Note 3. Significant Accounting Policies

The significant accounting policies that the Company follows are:

- 98 -

Table of Contents

Interim Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended January 31, ~~2023~~2024, and notes thereto and other pertinent information contained in our Form 10-K that we filed with the Securities and Exchange ~~Commission~~ Commission (the “SEC”).

The results of operations for the ~~nine~~three month period ended ~~October~~April 3130, ~~2023,~~2024 are not necessarily indicative of the results to be expected for the full fiscal year ending January 31, ~~2024~~2025.

Basis of Presentation

The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The consolidated financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Consolidated Financial Statements

The consolidated financial statements of the Company include the accounts of the Company and its wholly owned subsidiaries, Diamond Anvil Designs, LLC Deity Corporation and Vivis Corporation (Vivis), from the date of their formations or acquisition. Significant intercompany transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Inventory

Inventory is comprised of packaging and supplies and at times raw materials. Inventory is valued at cost, based on the average cost method, unless and until the net realizable value for the inventory is lower than cost, in which case an allowance is established to reduce the valuation to the net realizable value. As of ~~October 31~~April 30, ~~2023,~~2024 and January 31, ~~2023~~2024, market values of all of our inventory were greater than cost, and accordingly, no such valuation allowance was recognized.

Property and Equipment, net

Property and equipment consist of equipment used to manufacture the Company’s products and is presented at cost. Depreciation is recognized over the useful life of the equipment on a straight-line basis over three years beginning when the asset is put in service. For the ~~nine~~three months ended ~~October~~April 3130, ~~2023,~~2024 and ~~2022~~2023, the Company recognized depreciation expense of $411,~~816~~121 and $5919,~~179~~726, respectively.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts With Customers. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized based on the following five step model:

•	Identification of the contract with a customer

•	Identification of the performance obligations in the contract

•	Determination of the transaction price

•	Allocation of the transaction price to the performance obligations in the contract

•	Recognition of revenue when, or as, the Company satisfies a performance obligation

- 109 -

Table of Contents

Product sales are recognized all of the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. Payment is received before shipment of the product. Net revenues comprise gross revenues less customer discounts and allowances, actual and expected returns. Shipping charges billed to customers are included in net sales. Various taxes on the sale of products to customers are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. The Company allows for customers to return unopened products within 10 days in certain limited circumstances. There have been no refunds processed for returned product.

The Company also provides consulting services of business development. The revenue from this contract is recognized over time as the customer receives the benefit of the services under the contract.

For the three months ended April 30, 2024, revenue from consulting income from business development consulting services to one customer $29,420 and revenue from sales of CBD products totaled $2,955. Revenue for the three months ended April 30, 2023 consisted entirely of sales of CBD products.

Contract Costs

Costs incurred to obtain a customer contract are not material to the Company. The Company elected to apply the practical expedient to not capitalize contract costs to obtain contracts with a duration of one year or less, which are expensed and included within cost of goods and services.

Cost of Sales

Cost of sales includes all of the costs to purchase and assemble the Company’s products. Products are manufactured for the Company by third-party contractors, such costs represent the amounts invoiced by the contractors. Additionally, shipping costs are included in Cost of Sales in the Statements of Operations.

Earnings (Loss) per Common Share

We compute basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share. The basic earnings (loss) per common share are calculated by dividing our net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing our net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported.

Commitments and Contingencies

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

As discussed in more detail in Note 5, the Company agreed to pay 60% of all revenue from Deity Corporation to Sydney Jim, the Company’s CEO, up until a total of $250,000 is paid to Mr. Jim, at which point he will be entitled to 20% of revenue from Deity Corporation.

There were no other known commitments or contingencies as of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024.

Mezzanine equity

Where ordinary or preferred shares are determined to be conditionally redeemable upon the occurrence of certain events that are not solely within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders, they are classified as ‘mezzanine equity’ (temporary equity). The purpose of this classification is to convey that such a security may not be permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future.

- 10 -

Table of Contents

Subsequent events

The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.

- 11 -

Table of Contents

Recently Adopted Accounting Pronouncements

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

Note 4. Property and equipment, net

Property and equipment consist of the following:

	October 31, 2023			January 31, 2023
	April 30, 2024			January 31, 2024
Equipment	$	236,717		$	236,717
Total property and equipment		236,717			236,717
Less: accumulated depreciation		(~~229~~236,~~173~~717	)		(~~187~~235,~~357~~596	)
Property and equipment, net	$	~~7,544~~—		$	491,~~360~~121

For the three months ended April 30, 2024 and 2023, the Company recognized depreciation expense of $1,121 and $19,726, respectively.

Note 5. Related Party Transactions

During the ~~nine~~three months ended ~~October~~April 3130, ~~2023,~~2024 and ~~2022~~2023, we incurred salary expense of $7525,000 to our CEO, Sydney Jim. In addition, we incurred commission expense of $61,~~879~~773 and $263,~~101~~505 during the ~~nine~~three months ended ~~October~~April 3130, ~~2023,~~2024 and ~~2022~~2023, respecitively, to Mr. Jim and owed a total of $4144,~~475~~828 and $3443,~~596~~055 in accrued commissions as of ~~October~~April 3130, ~~2023,~~ 2024 and January 31, ~~2023~~2024, respectively. During the ~~nine~~three months ended ~~October~~April 3130, ~~2023~~2024, Mr. Jim paid expenses of $411,~~253~~ 938 on behalf of the Company.

As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, we owed Mr. Jim, or entities controlled by him, $~~407~~384,~~768~~866 and $~~233~~380,~~087~~555 which is recorded on the balance sheet in “Accounts Payable – Related Party”, respectively, and $12,314 ~~and $2,314~~ in “Advances payable to related party~~”, respectively~~. ~~This balance includes the commissions payable to Mr. Jim described above.~~”

During the ~~nine~~three months ended ~~October~~April 3130, 2023, an investor advanced $10,000 to the Company. This advance is unsecured, non-interest bearing and due on demand.

On March 11, 2022, the Company entered into a loan agreement for $60,000 of proceeds with the holder of the Company’s Series A and B preferred stock. The loan is unsecured and bears interest at 6%. The Company will make monthly payments of $4,240 per month beginning in April 2022 through the maturity at June 18, 2023. As of ~~October~~April 3130, ~~2023~~2024, the note principal balance was $54,156 and accrued interest was $46,~~322~~043. The Company has not made all ~~the~~ required monthly payments under the note agreement to date and the loan is currently in default.

During the year ended January 31, 2022, the Company acquired the assets of Deity Corporation, a Texas corporation which the Sydney Jim, the Company’s CEO, had a controlling interest in that will produce hemp and cannabis products. The transaction was considered an asset acquisition, as there were no operations of Deity Corporation prior to the transaction. The Company received the formulas for certain hemp and cannabis-based products and a website to market the products that will be produced. In exchange, the Company will pay to Mr. Jim 60% of the revenue from Deity Corporation sales until a total of $250,000 is reached, at which point the Company will pay 20% of Deity Corporation revenue to Mr. Jim.

Note 6. Advances and Notes Payable

As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, we had amounts due under advances of $3,450 at each period. These advances are not collateralized, non-interest bearing and are due on demand.

On- ~~March~~ 11, 2022, the Company entered into a loan agreement for $60,000 of proceeds with the holder of the Company’s Series A and B preferred stock. The loan is unsecured and bears interest at 6%. The Company will make monthly payments of $4,240 per month beginning in April 2022 through the maturity at June 18, 2023. As of October 31, 2023, the note principal balance was $54,156 and accrued interest was $4,322.-

- 12 -

Table of Contents

On March 11, 2022, the Company entered into a loan agreement for $60,000 of proceeds with the holder of the Company’s Series A and B preferred stock. The loan is unsecured and bears interest at 6%. The Company will make monthly payments of $4,240 per month beginning in April 2022 through the maturity at June 18, 2023. As of April 30, 2024, the note principal balance was $54,156 and accrued interest was $6,043. The Company has not made all required monthly payments under the note agreement to date and the loan is currently in default.

Note 7. Shareholders’ Equity

Series A Preferred Stock. In January 2020, our board of directors designated 50,000 shares of our preferred stock as Series A Preferred Stock which rank subordinate to all shares of common stock and do not have voting rights. The Series A Preferred Stock has a stated value of $5 per share. The Series A Preferred Stock is entitled to receive dividends of 10% of the net profit of VIVIS Corporation. The holders of the Series A Preferred Stock have the option to convert each share into 800 shares of common stock of the Company. As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, there are 50,000 shares of Series A Preferred Stock outstanding.

Series B Preferred Stock. In July 2020, our board of directors designated 10,000 shares of our preferred stock as Series B Preferred Stock which rank subordinate to all shares of common stock and do not have voting rights. The Series B Preferred Stock has a stated value of $5 per share. The Series B Preferred Stock is entitled to receive dividends of 0.4% of the net profit of VIVIS Corporation. Holders of the Series B Preferred Stock have the option to convert each share into 800 shares of common stock. During the year ended January 31, 2021, the Company subscribed 10,000 shares of Series B Preferred Stock for cash proceeds of $50,000. The shares were issued during the year ended January 31, 2022. As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, there are 10,000 shares of Series B Preferred Stock outstanding.

Series C Preferred Stock. In November 2020, our board of directors designated 40,000 shares of our preferred stock as Series C Preferred Stock which rank subordinate to all shares of common stock and do not have voting rights. The Series C Preferred Stock has a stated value of $5 per share. The Series C Preferred Stock is entitled to receive dividends of 10% of the net profit of VIVIS Corporation. After the Series C Preferred Stock has received cumulative dividends of $500,000, the dividend rate will reduce to 1%. Holders of the Series C Preferred Stock have the option to convert each share into 38 shares of common stock. During the year ended January 31, 2021, the Company subscribed 40,000 shares of Series B Preferred Stock for cash proceeds of $200,000. The shares were issued during the year ended January 31, 2022. As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, there are 40,000 shares of Series C Preferred Stock outstanding.

Series E preferred stock issued for services

On November 13, 2015, our board of directors designated 1,000,000 shares of our preferred stock as Series E Preferred Stock. The Series E Preferred Stock is subordinated to our common stock. It does not receive dividends and does not participate in equity distributions. The Series E Preferred stock has 2 votes for each outstanding share of common stock in the company. As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, there are 1,000,000 shares Series E Preferred Stock outstanding. Dividends, when, as and if declared by the Board of Directors, shall be paid out of funds at the time legally available for such purposes.

Series F preferred stock issued for services

The Series F Preferred Stock is subordinated to our common stock and superior to all shares of Preferred Stock. It does not receive dividends and does not participate in equity distributions. The Series F Preferred stock retains 2/3 of the voting rights in the company. During the year ended January 31, 2021, the Company issued 1,000,000 shares of Series F Preferred Stock to Sydney Jim, our CEO, in exchange for services. As of the date of this report, there are 1,000,000 shares Series F Preferred Stock outstanding. As of ~~October~~April 3130, ~~2023,~~2024 and January 31, ~~2023~~2024, there are 1,000,000 shares of Series F Preferred Stock outstanding.

Series G convertible preferred stock

During the ~~nine~~three months ended ~~October~~April 3130, 2023, the Company the holder of the Series G convertible preferred stock converted 35,200 shares and accrued dividends of $1,408 into 174,323,810 shares of common stock. During the ~~nine~~three months ended ~~October~~April 3130, 2022, the Company accrued dividends of $32,~~532~~429, and the holder of the Series G convertible preferred stock converted ~~250~~217,~~000~~800 shares and accrued dividends of $108,~~000~~712 into ~~518~~425,~~644~~622,~~372~~150 shares of common stock. The conversions were in accordance with the terms of the agreement and no gain or loss was recognized. As of ~~October~~April 3130, ~~2023~~ 2024, there were no shares of Series G convertible preferred stock outstanding.

Preferred Stock Subscription

On February 23, 2022, the Company sold 10,000 shares of preferred stock not yet designated for cash proceeds of $50,000.

- 1312 -

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and plan of operations should be read in conjunction with our financial statements and related notes appearing elsewhere herein. This discussion and analysis contains forward-looking statements including information about possible or assumed results of our financial conditions, operations, plans, objectives, and performance that involve risk, uncertainties, and assumptions. The actual results may differ materially from those anticipated in such forward-looking statements. For example, when we indicate that we expect to increase our product sales and potentially establish additional license relationships, these are forward-looking statements. The words expect, anticipate, estimate or similar expressions are also used to indicate forward-looking statements.

Background of our Company

Neutra Corp. was incorporated in Florida on January 11, 2011. On October 5, 2015, we reincorporated from Florida to Nevada. On August 16, 2019, we reincorporated from Nevada to Wyoming. The reincorporation was approved by our board of directors and by the holders of a majority of the voting rights for our common stock. There was no change in share ownership as a result of the reincorporation. Our authorized shares in the Wyoming corporation are unlimited shares of common stock and 20,000,000 shares of preferred stock.

We have established a fiscal year end of January 31.

We have generated limited revenues to date and our activities have been primarily limited to developing our business plan and research and development of products. We will not have the necessary capital to fully develop or execute our business plan until we are able to secure additional financing. There can be no assurance that such financing will be available on suitable terms. We need to raise additional funds in order to implement our business plan. Our current cash on hand is insufficient to commercialize our products or fully develop our business strategy. If we are unable to raise adequate additional funds or if those funds are not available on terms that are acceptable to us, we will not be able to execute our business plan and we may cease operations.

Plan of Operations

We believe we do not have adequate funds to fully execute our business plan for the next twelve months unless we obtain additional funding. However, should we not raise this capital, we will allocate our funding to first assure that all State, Federal and SEC requirements are met.

As of ~~October~~April 3130, ~~2023~~2024, we had cash on hand of $~~692~~333.

We intend to pursue capital through public or private financing, as well as borrowing and other sources in order to finance our business activities. We cannot guarantee that additional funding will be available on favorable terms, if at all. If adequate funds are not available, then our ability to continue our operations may be significantly hindered.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends, and other factors that management believes to be important at the time the consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

For a full description of our critical accounting policies, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report for the year ended January 31, ~~2023,~~2024 on Form 10-K.

- 1413 -

Table of Contents

Results of Operations

Three months ended ~~October~~April 3130, ~~2023~~2024 compared to ~~the~~ the three months ended ~~October~~April 3130, ~~2022.~~2023

Revenue and Cost of Goods Sold

During the three months ended April ~~October 31~~30, ~~2023~~2024, we recognized revenue of $132,~~311~~375 and cost of goods sold of $~~722~~1,420. ~~related~~For the three months ended April 30, 2024, revenue from consulting income from business development consulting services to ~~the~~one customer $29,420 and revenue from sales of CBD products totaled $2,955. During the three months ended ~~October 31~~April 30, ~~2022~~2023, we recognized revenue of $235,~~383~~842 and cost of goods sold of $123,~~708~~038 related to ~~the sales of~~ CBD ~~products. The decrease in revenue~~ ~~compared~~product ~~to the prior year is due to a slowdown in current economic conditions~~sales.

Depreciation

We recognized depreciation ~~expense~~ of $91,~~051~~121 and $19,726 ~~for~~ for the three months ended ~~October~~April 3130, ~~2023,~~2024 and ~~2022,~~2023 ~~respectively,~~ related to the Company’s property and equipment.

General and Administrative Expenses

We recognized general and administrative expenses of $43,~~487~~546 and $4650,~~439~~781 for the three months ended ~~October~~April 3130, ~~2023,~~2024 and ~~2022~~2023, respectively. The decrease is primarily related to the decrease in wages and professional fees.

Interest Expense

Interest expense was $~~2,258~~867 and $~~15,718~~199 for the three ~~months~~ months ended ~~October~~April 3130, ~~2023,~~2024 and ~~2022~~2023, respectively. ~~The decrease in interest expense was related to the settlement of outstanding convertible notes payable in the prior year.~~

Net Loss

We incurred a net loss of $5416,~~986~~352 for the three months ended ~~October~~April 3130, ~~2023,~~2024 as compared to $8171,~~792~~996 for the comparable period of ~~2022~~2023.

Nine months ended October 31, 2023, compared to the nine months ended October 31, 2022.

Revenue and Cost of Goods Sold

During the nine months ended October 31, 2023, we recognized revenue of $11,478 and cost of goods sold of $6,403 related to the sales of CBD products. During the nine months ended October 31, 2022, we recognized revenue of $62,077 and cost of goods sold of $29,725 related to the sales of CBD products. The decrease in revenue compared to the prior year is due to a slowdown in current economic conditions.

Depreciation

We recognized depreciation expense of $41,816 and $59,179 for the nine months ended October 31, 2023, and 2022 related to the Company’s property and equipment.

General and Administrative Expenses

We recognized general and administrative expenses of $152,085 and $186,958 for the nine months ended October 31, 2023, and 2022, respectively. The decrease is primarily related to the decrease in wages and professional fees.

Interest Expense

Interest expense was $2,486 and $46,528 for the nine months ended October 31, 2023, and 2022, respectively. The decrease in interest expense was related to the settlement of outstanding convertible notes payable in the prior year.

Net Loss

We incurred a net loss of $198,829 for the nine months ended October 31, 2023, as compared to $286,414 for the comparable period of 2022.

- 15 -

Table of Contents

Liquidity and Capital Resources

At ~~October~~April 3130, ~~2023~~2024, we had cash on hand of $~~692~~333. We We have negative working capital ~~deficit~~ of $~~889~~987,~~428~~030. Net cash used in operating activities for the ~~nine~~three months ended ~~October~~April 3130, ~~2023,~~2024 was $111,~~277~~299. The Company had net cash provided by investing and financing activities of $~~10,000~~0 for the ~~nine~~three months ended ~~October~~April 3130, ~~2023, with $10,000 of proceeds from advances from related party~~2024. Cash on hand is not adequate to fund our operations for ~~the~~less ~~next~~than ~~twelve~~six months. We do not expect to achieve positive cash flow from operating activities in the near future. We will require additional cash in order to implement our business plan. There is no guarantee that we will be able to attain fund when we need them or that funds will be available on terms that are acceptable to us. We have no material commitments for capital expenditures as of ~~October~~April 3130, ~~2023~~2024.

Additional Financing

Additional financing is required to continue operations. Although actively searching for available capital, we do not have any current arrangements for additional outside sources of financing and cannot provide any assurance that such financing will be available.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

- 14 -

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

This item is not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Management’s Report on Internal Control over Financial Reporting

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of ~~October~~April 3130, ~~2023~~2024. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of ~~October~~April 3130, ~~2023~~2024, our disclosure controls and procedures were not effective to ensure that information required to be disclosed in reports filed by us under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

1. As of ~~October~~April 3130, ~~2023~~2024, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees our accounting policies and procedures. This has resulted in inconsistent practices. Further, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness. 2. As of ~~October~~April 3130, ~~2023~~2024, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness. 3. As of ~~October~~April 3130, ~~2023~~2024, we did not maintain effective controls over transactions with related parties. Specifically, controls were not designed and in place to ensure that all transactions with related parties were captured and tracked in our financial statements. The Company has no formal process related to the identification and approval of related party transactions. Management has determined that this control deficiency constitutes a material weakness.

Our management, including our principal executive officer and principal financial officer, who is the same person, does not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

- 16 -

Table of Contents

Change in Internal Controls Over Financial Reporting

There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

- 15 -

Table of Contents

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder are an adverse party or has a material interest adverse to us.

ITEM 1A. RISK FACTORS

This item is not applicable to smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

We have not defaulted upon senior securities.

ITEM 4. MINE SAFETY DISCLOSURES

This item is not applicable to the Company.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.	Description
3.1	Articles of Incorporation (1)
3.2	Bylaws (1)
14.1	Code of Ethics (1)
21	Subsidiaries of the Registrant (2)
31.1	Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer and principal financial and accounting officer. (2)
32.1	Section 1350 Certification of principal executive officer and principal financial accounting officer. (2)
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. (3)
101.SCH	Inline XBRL Taxonomy Extension Schema Document (3)
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document (3)
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document (3)
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document (3)
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document (3)
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). (3)

__________

(1)	Incorporated by reference to our Form S-1 filed with the Securities and Exchange Commission on February 24, 2011.
(2)	Filed or furnished herewith.
(3)	InTo ~~accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall~~ be ~~deemed~~filed ~~“furnished”~~by ~~and not “filed~~amendment.”

- 1716 -

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Neutra Corp.
Date: December 15, 2023	BY: /s/ Sydney Jim
Date: August 7, 2024	BY: /s/ Sydney Jim
	Sydney Jim
	President, Secretary, Treasurer, Principal Executive Officer, Principal Financial and Accounting Officer, and Sole Director

- 1817 -

Filing Compare · NEUTRA CORP.